ERYTECH Pharma (ERYP) Competitors

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Notice: This company has been marked as potentially delisted and may not be actively trading.

Stock Analysis Competitors Headlines Social Media

ERYP vs. SGMO, ATHA, PLX, GRTS, DTIL, CVM, ZURA, CRIS, OTLK, and VIGL

Should you be buying ERYTECH Pharma stock or one of its competitors? The main competitors of ERYTECH Pharma include Sangamo Therapeutics (SGMO), Athira Pharma (ATHA), Protalix BioTherapeutics (PLX), Gritstone bio (GRTS), Precision BioSciences (DTIL), CEL-SCI (CVM), Zura Bio (ZURA), Curis (CRIS), Outlook Therapeutics (OTLK), and Vigil Neuroscience (VIGL). These companies are all part of the "biological products, except diagnostic" industry.

ERYTECH Pharma vs.

ERYTECH Pharma (NASDAQ:ERYP) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, community ranking, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

: Sangamo Therapeutics received 276 more outperform votes than ERYTECH Pharma when rated by MarketBeat users. Likewise, 62.75% of users gave Sangamo Therapeutics an outperform vote while only 57.45% of users gave ERYTECH Pharma an outperform vote.
Company Underperform Outperform
ERYTECH Pharma Outperform Votes
162
57.45%
Underperform Votes
120
42.55%
Sangamo Therapeutics Outperform Votes
438
62.75%
Underperform Votes
260
37.25%
: In the previous week, ERYTECH Pharma's average media sentiment score of 0.00 equaled Sangamo Therapeutics'average media sentiment score.
Company Overall Sentiment
ERYTECH Pharma Neutral
Sangamo Therapeutics Neutral
: ERYTECH Pharma has a beta of 2.69, suggesting that its share price is 169% more volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.
: 1.1% of ERYTECH Pharma shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 1.9% of ERYTECH Pharma shares are held by insiders. Comparatively, 3.0% of Sangamo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
: Sangamo Therapeutics has a consensus price target of $4.93, suggesting a potential upside of 915.25%. Given Sangamo Therapeutics' higher possible upside, analysts plainly believe Sangamo Therapeutics is more favorable than ERYTECH Pharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ERYTECH Pharma
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
Sangamo Therapeutics
1 Sell rating(s)

3 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.29
: ERYTECH Pharma has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -146.30%. ERYTECH Pharma's return on equity of 0.00% beat Sangamo Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
ERYTECH Pharma N/A N/A N/A
Sangamo Therapeutics -146.30% -82.17% -56.21%
: ERYTECH Pharma has higher earnings, but lower revenue than Sangamo Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ERYTECH Pharma $32.66M 3.24 -$240K N/A N/A
Sangamo Therapeutics $176.23M 0.49 -$257.83M -$1.47 -0.33

Company	Underperform	Outperform
ERYTECH Pharma	Outperform Votes 162 57.45%	Underperform Votes 120 42.55%
Sangamo Therapeutics	Outperform Votes 438 62.75%	Underperform Votes 260 37.25%

Company	Overall Sentiment
ERYTECH Pharma	Neutral
Sangamo Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ERYTECH Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Sangamo Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Company	Net Margins	Return on Equity	Return on Assets
ERYTECH Pharma	N/A	N/A	N/A
Sangamo Therapeutics	-146.30%	-82.17%	-56.21%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ERYTECH Pharma	$32.66M	3.24	-$240K	N/A	N/A
Sangamo Therapeutics	$176.23M	0.49	-$257.83M	-$1.47	-0.33

Summary

Sangamo Therapeutics beats ERYTECH Pharma on 7 of the 13 factors compared between the two stocks.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

Get ERYTECH Pharma News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ERYP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ERYP vs. The Competition

Export to Excel

Metric	ERYTECH Pharma	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$105.77M	$2.54B	$4.74B	$7.44B
Dividend Yield	N/A	2.29%	2.98%	4.00%
P/E Ratio	N/A	30.06	230.61	17.32
Price / Sales	3.24	279.61	2,315.02	83.13
Price / Cash	N/A	143.37	46.92	35.12
Price / Book	3.88	3.50	4.58	4.19
Net Income	-$240,000.00	-$44.11M	$103.98M	$214.01M

ERYTECH Pharma Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGMO Sangamo Therapeutics	0.5302 of 5 stars	$0.56 flat	$4.93 +775.7%	-69.5%	$100.62M	$176.23M	-0.38	405	Positive News
ATHA Athira Pharma	2.0376 of 5 stars	$2.52 +4.1%	$12.00 +376.2%	-21.1%	$96.59M	N/A	-0.82	65
PLX Protalix BioTherapeutics	2.598 of 5 stars	$1.32 +1.5%	$10.00 +657.6%	N/A	$96.43M	$65.49M	26.41	208
GRTS Gritstone bio	1.825 of 5 stars	$0.98 -3.0%	$6.33 +547.1%	-71.7%	$95.98M	$16.34M	-0.82	231	Analyst Revision
DTIL Precision BioSciences	3.7447 of 5 stars	$13.84 +2.3%	$60.00 +333.5%	-60.7%	$95.77M	$48.73M	-0.86	115	Analyst Report
CVM CEL-SCI	0 of 5 stars	$1.71 -3.9%	N/A	N/A	$92.31M	N/A	-2.51	N/A	Analyst Revision
ZURA Zura Bio	2.8582 of 5 stars	$2.77 -0.7%	$16.40 +492.1%	-62.7%	$119.36M	N/A	0.00	N/A	News Coverage Positive News Gap Up
CRIS Curis	1.6792 of 5 stars	$15.58 -5.6%	$37.33 +139.6%	-20.9%	$91.83M	$10.02M	-1.74	49	News Coverage Gap Up
OTLK Outlook Therapeutics	3.0131 of 5 stars	$9.26 -1.0%	$46.43 +401.3%	-62.0%	$120.47M	N/A	-2.32	24	Gap Up
VIGL Vigil Neuroscience	1.9908 of 5 stars	$3.31 -4.9%	$17.40 +425.7%	-72.5%	$122.09M	N/A	-1.55	69	Analyst Report Positive News

Related Companies and Tools

Related Companies:

Top 10 Stock Comparisons

This page (NASDAQ:ERYP) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ERYTECH Pharma (ERYP) Competitors

ERYP vs. SGMO, ATHA, PLX, GRTS, DTIL, CVM, ZURA, CRIS, OTLK, and VIGL

ERYTECH Pharma vs.

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERYP vs. The Competition

ERYTECH Pharma Competitors List

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info